secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001824293-22-000084
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon Pharmaceuticals receives Nasdaq delisting notice after failing to regain $1 bid price compliance
--------------------------------------------------------------------------------

- Nasdaq notified Vallon on Dec 28 that its stock will be suspended Jan 6 unless hearing is requested.
- Company failed to regain compliance with minimum $1.00 bid price by Dec 27 deadline because it lacks $5M in stockholders' equity.
- Vallon will request a hearing before Nasdaq Hearings Panel to stay delisting; no assurance of extension.
- A reverse stock split proposal is pending shareholder vote to address bid price; special meeting scheduled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429322000084/0001824293-22-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429322000084/val-20221228.htm
  HTML page:      https://secwatch.observer/filing/0001824293-22-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer